Upgrade to SI Premium - Free Trial

Stifel Reiterates Buy Rating on Rhythm Pharmaceuticals (RYTM) Post Release of Setmelanotide Data

June 15, 2026 9:31 AM
Stifel analyst Paul Matteis reiterated a Buy rating and $133.00 price target on Rhythm Pharmaceuticals (NASDAQ: RYTM).The analyst commented, "We're ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments